mdxhealth
Molecular Diagnostic Solutions for Prostate Cancer
Molecular Diagnostic Solutions for Prostate Cancer
Mdxhealth is a multinational healthcare company focusing on providing actionable molecular diagnostic information to customize the diagnosis and treatment of cancer. Utilizing proprietary genetic, epigenetic (methylation), and other molecular technologies, the company offers tests that aid physicians in diagnosing urologic cancers, forecasting recurrence risk, and anticipating the response to specific therapies. Mdxhealth was established in 2003 and has its European headquarters in Herstal, Belgium, with laboratory operations in Nijmegen, the Netherlands. Its US headquarters and laboratory operations are based in Irvine, California. The company operates in the biotechnology sector. The latest investment in the company amounted to $37.00M, in the form of a Post-IPO Equity investment on 03 February 2023. The specific investors involved in this latest funding round have not been disclosed.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $37.00M | - | 03 Feb 2023 | |
| Post-IPO Debt | $35.00M | 1 |
|
02 Aug 2022 |
| Post-IPO Equity | $14.00M | 1 | MVM Life Science Partners | 27 Apr 2020 |
| Post-IPO Equity | €9.00M | - | 27 Sep 2019 | |
| Grant | €71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Dec 2018 |
No recent news or press coverage available for mdxhealth.
We care about your data, and we'd love to use cookies make your experience better.
